Art. -Nr.: HY-163319

NCA029

Kundenbewertung

Based on 1 Customer Validation

NCA029 is a potent and selective homo sapiens caseinolytic protease P (HsClpP) activator with an EC₅₀ of 0.15 μM. NCA029 acts on HsClpP to activate an ATF3-dependent integrative stress response, leading to colon cancer cell death.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.24%
CAS. Nr.: 3032667-94-7
Formel: C₂₂H₂₀F₃N₃O
Molecular Weight:399.41

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

NCA029 Chemical Structure

CAS. Nr.: 3032667-94-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	3.1 μM Compound: 3-19e; NCA029	Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
H9c2	IC₅₀	60.6 μM Compound: 3-19e; NCA029	Antiproliferative activity against rat H9c2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against rat H9c2 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
HCT-116	IC₅₀	1 μM Compound: 3-19e; NCA029	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
HCT-15	IC₅₀	3.5 μM Compound: 3-19e; NCA029	Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
HEK293	IC₅₀	78.1 μM Compound: 3-19e; NCA029	Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
L02	IC₅₀	64.1 μM Compound: 3-19e; NCA029	Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
SW480	IC₅₀	5.4 μM Compound: 3-19e; NCA029	Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]
SW-620	IC₅₀	1.5 μM Compound: 3-19e; NCA029	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 method	[PMID: 38329974]

In Vitro

NCA029 inhibits human colon adenocarcinoma (COAD) cell lines with IC₅₀ values of 1.1 μM, 1.5 μM, 3.5 μM, 5.4 μM, and 3.1 μM for HCT116, SW620, HCT15, SW480, and DLD-1, respectively^[1].
NCA029 causes an increase in intracellular ROS levels in HCT116 cells in a dose-dependent manner, indicating impaired respiratory chain activity^[1].
NCA029 (0.5-2 μM; 48 h) inhibits tumor cell proliferation and metastasis^[1].
NCA029 (0.5-2 μM; 48 h) dose-dependently induces apoptosis and arrests cells with G2/M phase in HCT116 cells^[1].
NCA029 (0.5-2 μM) dose-dependently reduces the expression of SDHB and up-regulated the expression of the pro-apoptotic protein BAX, while down-regulating the expression of the antiapoptotic protein Bcl-2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:

HCT116 cells
Concentration:

0.5 μM, 1 μM, 2 μM
Incubation Time:

48 h
Result:

Resulted in a dose-dependent reduction in HCT116 clone formation ability.

Cell Cycle Analysis^[1]

Cell Line:

HCT116 cells
Concentration:

0.5 μM, 1 μM, 2 μM
Incubation Time:

48 h
Result:

Significantly increased the number of cells in the G2 phase.

In Vivo

NCA029 (1.25-5 mg/kg; iv; twice weekly; for 21 days) significantly inhibits tumor growth in HCT116 xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c nude mice bearing HCT116 tumors^[1]
Dosage:

1.25, 2.5, and 5 mg/kg
Administration:

intravenous administration; twice weekly; for 21 days
Result:

Inhibited tumor growth in mice xenograft model.

Chemical Information

CAS. Nr. 3032667-94-7
Appearance Oil
Molecular Weight 399.41
Formel C₂₂H₂₀F₃N₃O
Color Colorless to light yellow
SMILES

N#CC1=CC=CC(CN2CCC=C(C2)C(NCC3=CC=C(C=C3)C(F)(F)F)=O)=C1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (250.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5037 mL

12.5185 mL

25.0369 mL

5 mM

0.5007 mL

2.5037 mL

5.0074 mL

10 mM

0.2504 mL

1.2518 mL

2.5037 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jiangnan Zhang, et al. Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response. J Med Chem. 2024 Feb 22;67(4):2812-2836. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5037 mL	12.5185 mL	25.0369 mL	62.5923 mL
	5 mM	0.5007 mL	2.5037 mL	5.0074 mL	12.5185 mL
	10 mM	0.2504 mL	1.2518 mL	2.5037 mL	6.2592 mL
	15 mM	0.1669 mL	0.8346 mL	1.6691 mL	4.1728 mL
	20 mM	0.1252 mL	0.6259 mL	1.2518 mL	3.1296 mL
	25 mM	0.1001 mL	0.5007 mL	1.0015 mL	2.5037 mL
	30 mM	0.0835 mL	0.4173 mL	0.8346 mL	2.0864 mL
	40 mM	0.0626 mL	0.3130 mL	0.6259 mL	1.5648 mL
	50 mM	0.0501 mL	0.2504 mL	0.5007 mL	1.2518 mL
	60 mM	0.0417 mL	0.2086 mL	0.4173 mL	1.0432 mL
	80 mM	0.0313 mL	0.1565 mL	0.3130 mL	0.7824 mL
	100 mM	0.0250 mL	0.1252 mL	0.2504 mL	0.6259 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NCA029

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Anti-Colorectal Cancer Compound Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NCA029

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Anti-Colorectal Cancer Compound Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NCA029 Related Classifications

HY-163319 Related Classifications